HC Wainwright Analysts Lift Earnings Estimates for RAPT

Key Points

• HC Wainwright has raised its Q3 2025 earnings per share estimate for Rapt Therapeutics from ($1.17) to ($1.15) and maintains a "Buy" rating with a target price of $27.00.
• The stock has received mixed ratings from analysts, with a consensus rating of "Hold" and a price target averaging $21.43.
• Rapt Therapeutics recently reported earnings per share of ($0.65), missing the consensus estimate of ($0.61) by $0.04.

Rapt Therapeutics (NASDAQ:RAPT - Free Report) - Investment analysts at HC Wainwright increased their Q3 2025 EPS estimates for shares of Rapt Therapeutics in a research report issued on Thursday, August 7th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($1.15) per share for the quarter, up from their prior estimate of ($1.17). HC Wainwright currently has a "Buy" rating and a $27.00 price target on the stock. The consensus estimate for Rapt Therapeutics' current full-year earnings is ($2.14) per share. HC Wainwright also issued estimates for Rapt Therapeutics' Q4 2025 earnings at ($0.95) EPS, FY2025 earnings at ($1.24) EPS, FY2026 earnings at ($1.83) EPS, FY2027 earnings at ($1.23) EPS, FY2028 earnings at ($1.07) EPS and FY2029 earnings at ($1.12) EPS.

RAPT has been the topic of several other research reports. Wall Street Zen cut shares of Rapt Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday. JPMorgan Chase & Co. raised shares of Rapt Therapeutics from an "underweight" rating to a "neutral" rating and set a $14.00 target price on the stock in a report on Wednesday, July 30th. UBS Group set a $9.00 target price on shares of Rapt Therapeutics and gave the company a "neutral" rating in a report on Tuesday. Lifesci Capital raised shares of Rapt Therapeutics to a "strong-buy" rating and set a $31.00 price target on the stock in a report on Tuesday, July 22nd. Finally, Wells Fargo & Company reissued an "overweight" rating and issued a $38.00 price target (down previously from $51.00) on shares of Rapt Therapeutics in a report on Friday, August 8th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $21.57.

Rapt Therapeutics Stock Performance

NASDAQ RAPT traded down $0.27 on Monday, hitting $10.64. The stock had a trading volume of 527,689 shares, compared to its average volume of 113,389. The firm has a 50-day moving average of $9.55 and a 200-day moving average of $8.80. The company has a market capitalization of $175.88 million, a price-to-earnings ratio of -0.75 and a beta of 0.01. Rapt Therapeutics has a 52-week low of $5.67 and a 52-week high of $26.56.

Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.04).

Institutional Investors Weigh In On Rapt Therapeutics

A number of large investors have recently modified their holdings of RAPT. Sei Investments Co. purchased a new position in Rapt Therapeutics during the 4th quarter valued at about $64,000. Nuveen Asset Management LLC lifted its position in Rapt Therapeutics by 50.5% during the 4th quarter. Nuveen Asset Management LLC now owns 116,925 shares of the company's stock valued at $185,000 after acquiring an additional 39,216 shares during the period. Renaissance Technologies LLC lifted its position in Rapt Therapeutics by 25.5% during the 4th quarter. Renaissance Technologies LLC now owns 369,736 shares of the company's stock valued at $584,000 after acquiring an additional 75,136 shares during the period. JPMorgan Chase & Co. lifted its position in Rapt Therapeutics by 1,128.3% during the 4th quarter. JPMorgan Chase & Co. now owns 205,164 shares of the company's stock valued at $324,000 after acquiring an additional 188,461 shares during the period. Finally, Comerica Bank purchased a new position in Rapt Therapeutics in the fourth quarter worth about $92,000. Institutional investors own 99.09% of the company's stock.

Rapt Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.